San Diego based medical software developer CorTechs Labs announced that it has entered into a partnership agreement with multinational pharmaceutical maker Novartis Pharma AG. The two companies will collaborate in further development of Cortechs’ powerful NeuroQuant breakthrough 510(k) cleared software brain volume quantification device that targets identification, measurement and tracking of brain volume loss in multiple sclerosis (MS) patients. NeuroQuant is designed to make quantitative MRI measurement and analysis of MRI images of the human brain and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device, a routine part of clinical practice.
A NeuroQuant report provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. It enables clinicians to conduct sophisticated, automated, accurate, and consistent measurements of the whole brain, the left and right thalami and the lateral ventricles using data from 3D T1 MRI images, and targets identification and tracking of neuro-degeneration in these sub-cortical structures.
Non-invasive, inexpensive and accurate, NeuroQuant is used to verify Alzheimer’s in patients 50-95, assessment of epilepsy and multiple sclerosis in patients 18 and older, traumatic brain injury in NFL players, boxers and soldiers, and more. Cortechs’ technologies provide physicians with the objective information they need to confirm or refute a projected diagnosis.
~~~~~~~~~~~~~~~~~~~~
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews